The company was founded in 1927 by Julius Wolf and Alfred Voss in Hamburg under the name Nordmark-Werke AG. Nordmark moved to Uetersen/Moorrege near Hamburg in 1943. The company's core competency is the manufacture of pharmaceuticals with active biological ingredients. The company was sold in 1968 to BASF AG, which transferred its shares to Knoll AG in 1983. Nordmark became independent again in 2001 and operates under the name Nordmark Arzneimittel GmbH & Co. KG. Nordmark continuously produces new and improved products based on in-house development know-how, science and technology, keeping pace with ever changing regulatory requirements. The main active drug substance produced in Uetersen is pancreatin, an extract containing vital digestive enzymes obtained from porc pancreas glands. Nordmark has served the healthcare community with this product for three decades. The Company's product range embraces a selection of product grades, extensive analytical services and documentation. The Company also manufactures custom-made products and finished pharmaceuticals to individual customers' specifications. Nordmark is specialized in development of active biological ingredients; manufacture of active biological ingredients, notably pancreatin, collagenase and heparin / low molecular weight heparin; production of medicinal products containing these active drug substances; pharmaceutical development; contract manufacture of pharmaceutica; manufacture of food supplements.